National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
14 04 2023
14 04 2023
Historique:
received:
28
10
2022
revised:
09
01
2023
accepted:
17
01
2023
medline:
17
4
2023
pubmed:
21
1
2023
entrez:
20
1
2023
Statut:
ppublish
Résumé
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer histology. Although many therapies are now approved for the treatment of cancers harboring specific genomic alterations, most patients do not respond to therapies targeting a single alteration. Further, when antitumor responses do occur, they are often not durable due to the development of drug resistance. Therefore, there is a great need to identify rational combination therapies that may be more effective. To address this need, the NCI and National Clinical Trials Network have developed NCI-ComboMATCH, the successor to NCI-MATCH. Like the original trial, NCI-ComboMATCH is a signal-seeking study. The goal of ComboMATCH is to overcome drug resistance to single-agent therapy and/or utilize novel synergies to increase efficacy by developing genomically-directed combination therapies, supported by strong preclinical in vivo evidence. Although NCI-MATCH was mainly comprised of multiple single-arm studies, NCI-ComboMATCH tests combination therapy, evaluating both combination of targeted agents as well as combinations of targeted therapy with chemotherapy. Although NCI-MATCH was histology agnostic with selected tumor exclusions, ComboMATCH has histology-specific and histology-agnostic arms. Although NCI-MATCH consisted of single-arm studies, ComboMATCH utilizes single-arm as well as randomized designs. NCI-MATCH had a separate, parallel Pediatric MATCH trial, whereas ComboMATCH will include children within the same trial. We present rationale, scientific principles, study design, and logistics supporting the ComboMATCH study.
Identifiants
pubmed: 36662819
pii: 716092
doi: 10.1158/1078-0432.CCR-22-3334
pmc: PMC10102840
mid: NIHMS1868727
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1412-1422Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233329
Pays : United States
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029
pubmed: 31922567
J Clin Oncol. 2020 Jan 20;38(3):214-222
pubmed: 31765263
Stat Med. 1994 Jul 15-30;13(13-14):1453-8
pubmed: 7973224
Clin Cancer Res. 2018 Feb 1;24(3):521-531
pubmed: 28839110
J Clin Oncol. 2022 Apr 10;40(11):1231-1258
pubmed: 35175857
Curr Probl Cancer. 2017 May - Jun;41(3):201-211
pubmed: 28625332
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
Clin Cancer Res. 2020 Apr 15;26(8):1812-1819
pubmed: 31924734
Ann Oncol. 2019 Nov 1;30(11):1821-1830
pubmed: 31504139
J Clin Oncol. 2022 Jul 10;40(20):2224-2234
pubmed: 35353553
JCO Precis Oncol. 2020 Oct 5;4:
pubmed: 33163848
JCO Precis Oncol. 2018;2018:
pubmed: 30603737
Curr Probl Cancer. 2017 May - Jun;41(3):182-193
pubmed: 28372823
Am Soc Clin Oncol Educ Book. 2020 May;40:115-126
pubmed: 32421454
Chin Clin Oncol. 2015 Sep;4(3):31
pubmed: 26408298
J Clin Oncol. 2020 Nov 20;38(33):3895-3904
pubmed: 32758030
J Clin Oncol. 2020 Jul 20;38(21):2407-2417
pubmed: 32463741
NPJ Precis Oncol. 2022 Mar 1;6(1):13
pubmed: 35233056
Clin Cancer Res. 2021 Jun 1;27(11):2996-3004
pubmed: 33637626
JCO Precis Oncol. 2022 Feb;6:e2100424
pubmed: 35138919
J Mol Diagn. 2017 Mar;19(2):313-327
pubmed: 28188106
Cancer Discov. 2022 Feb;12(2):402-415
pubmed: 34551969
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
J Clin Oncol. 2022 May 10;40(14):1552-1561
pubmed: 35133871
JAMA Oncol. 2021 Feb 1;7(2):271-278
pubmed: 33377972
J Clin Oncol. 2020 Nov 20;38(33):3883-3894
pubmed: 33048619
Semin Oncol. 2014 Jun;41(3):297-9
pubmed: 25023344
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622